The adipose tissue endocrine mechanism of the prophylactic protective effect of pioglitazone in high-fat diet-induced insulin resistance

Journal of International Medical Research

Volumn 40, Issue 4, 2012, Pages 1304-1316

  Gong, Y ^a   Li, J ^a   Li, C ^a   Mu, Y ^a   Xiao, Y ^a   Tian, H ^a   Pan, C ^a   Liu, Y ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Adiponectin; Glucose tolerance; Insulin resistance; Pioglitazone; Rats; Resistin

Indexed keywords

ADIPONECTIN; FATTY ACID; GLUCOSE; INSULIN; MESSENGER RNA; PALMITIC ACID; PIOGLITAZONE; RESISTIN; SMALL INTERFERING RNA; TRITIUM;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD GLUCOSE METER; CONTROLLED STUDY; DRUG EFFECT; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; ISOTOPE LABELING; LIPID DIET; LIVER; LIVER CELL CULTURE; MALE; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; RAT; SKELETAL MUSCLE; TISSUE DISTRIBUTION;

EID: 84867507999     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/147323001204000409     Document Type: Article

References (33)

1. Goossens GH: The role of adipose tissue dysfunction in the pathogenesis of obesityrelated insulin resistance. Physiol Behav 2008; 94: 206 - 218.
2. van de Woestijne AP, Monajemi H, Kalkhoven E, et al: Adipose tissue dysfunction and hypertriglyceridemia: mechanisms and management. Obes Rev 2011; 12: 829 - 840.
3. Shehzad A, Iqbal W, Shehzad O, et al: Adiponectin: Regulation of its production and its role in human diseases. Hormones (Athens) 2012; 11: 8-20.
4. Catalan V, Gómez-Ambrosi J, Rodriguez A, et al: Adipokines in the treatment of diabetes mellitus and obesity. Expert Opin Pharmacother 2009; 10: 239 - 254.
5. Yamauchi T, Kamon J, Ito Y, et al: Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762 - 769.
6. Kudoh A, Satoh H, Hirai H, et al: Pioglitazone upregulates adiponectin receptor 2 in 3T3-L1 adipocytes. Life Sci 2011; 88: 1055 - 1062.
7. Zhang D, Guo M, Zhang W, et al Adiponectin stimulates proliferation of adult hippocampal neural stem/progenitor cells through activation of p38 mitogen-activated protein kinase (p38MAPK)/glycogen synthase kinase 3β (GSK3β)/β-catenin signaling cascade. J Biol Chem 2011; 286: 44913-44920.
8. Luo R, Li X, Jiang R, et al: Serum concentrations of resistin and adiponectin and their relationship to insulin resistance in subjects with impaired glucose tolerance. J Int Med Res 2012; 40: 621 - 630.
9. Fujita H, Fujishima H, Morii T, et al: Effect of metformin on adipose tissue resistin expression in db/db mice. Biochem Biophys Res Commun 2002; 298: 345 - 349.
10. Kus V, Flachs P, Kuda O, et al: Unmasking differential effects of rosiglitazone and pioglitazone in the combination treatment with n-3 fatty acids in mice fed a high-fat diet. PLoS One 2011; 6: e27126.
11. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457 - 2471.
12. Stefan N, Peter A, Cegan A, et al: Low hepatic stearoyl-CoA desaturase 1 activity is associated with fatty liver and insulin resistance in obese humans. Diabetologia 2008; 51: 648 - 656.
13. Sanz MN, Sánchez-Martín C, Detaille D, et al: Acute mitochondrial actions of glitazones on the liver: A crucial parameter for their antidiabetic properties. Cell Physiol Biochem 2011; 28: 899-910.
14. Boettcher E, Csako G, Pucino F, et al: Metaanalysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2012; 35: 66 - 75.
15. Staiger H, Kaltenbach S, Staiger K, et al: Expression of adiponectin receptor mRNA in human skeletal muscle cells is related to in vivo parameters of glucose and lipid metabolism. Diabetes 2004; 53: 2195 - 2201.
16. Derosa G, Maffioli P: Peroxisome proliferatoractivated receptor-y (PPAR-y) agonists on glycemic control, lipid profile and cardiovascular risk. Curr Mol Pharmacol 2011; Epub ahead of print.
17. Shah PK, Mudaliar S, Chang AR, et al: Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13: 505-510.
18. Hsiao G, Chapman J, Ofrecio JM, et al: Multitissue, selective PPARy modulation of insulin sensitivity and metabolic pathways in obese rats. Am J Physiol Endocrinol Metab 2011; 300: E164-E174.
19. Sears DD, Hsiao G, Hsiao A, et al: Mechanisms of human insulin resistance and thiazolidinedione-mediated insulin sensitization. Proc Natl Acad Sci USA 2009; 106: 18745 - 18750.
20. Gastaldelli A, Harrison S, Belfort-Aguiar R, et al: Pioglitazone in the treatment of NASH: The role of adiponectin. Aliment Pharmacol Ther 2010; 32: 769 - 775.
21. Pita J, Panadero A, Soriano-Guillen L, et al: The insulin sensitizing effects of PPAR-y agonist are associated to changes in adiponectin index and adiponectin receptors in Zucker fatty rats. Regul Pept 2012; 174: 18-25.
22. Shadid S, Stehouwer CD, Jensen MD: Diet/exercise versus pioglitazone: effects of insulin sensitization with decreasing or increasing fat mass on adipokines and inflammatory markers. J Clin Endocrinol Metab 2006; 91: 3418 - 3425.
23. Li W, Tonelli J, Kishore P, et al: Insulinsensitizing effects of thiazolidinediones are not linked to adiponectin receptor expression in human fat or muscle. Am J Physiol Endocrinol Metab 2007; 292: El 301 - El 307.
24. Kuda O, Staňkova B, Tvrzicka E, et al: Prominent role of liver in elevated plasma palmitoleate levels in response to rosiglitazone in mice fed high-fat diet. J Physiol Pharmacol 2009; 60: 135 - 140.
25. Smith BW, Adams LA: Nonalcoholic fatty liver disease and diabetes mellitus: Pathogenesis and treatment. Nat Rev Endocrinol 2011; 7: 456 -465.
26. Polyzos SA, Kountouras J, Zavos C, et al: The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab 2010; 12: 365 - 383.
27. Tsuchida A, Yamauchi T, Ito Y, et al: Insulin/Foxol pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 2004; 279: 30817 - 30822.
28. Civitarese AE, Jenkinson CP, Richardson D, et al: Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of Type 2 diabetes. Diabetologia 2004; 47: 816 820.
29. Debard C, Laville M, Berbe V, et al: Expression of key genes of fatty acid oxidation, including adiponectin receptors, in skeletal muscle of Type 2 diabetic patients. Diabetologia 2004; 47: 917-925. (Pubitemid 38757006)
30. Wang H, Zhang H, Jia Y, et al: Adiponectin receptor 1 gene (ADIPORl) as a candidate for type 2 diabetes and insulin resistance. Diabetes 2004; 53: 2132 - 2136.
31. Viguerie N, Vidal H, Arner P, et al: Adipose tissue gene expression in obese subjects during low-fat and high-fat hypocaloric diets. Diabetologia 2005; 48: 123 - 131.
32. Tsuchida A, Yamauchi T, Takekawa S, et al: Peroxisome proliferator-activated receptor (PPAR)α activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARα, PPARγy, and their combination. Diabetes 2005; 54: 3358 - 3370.
33. Tian L, Luo N, Zhu X, et al:. AdiponectinAdipoRl/2-APPLl signaling axis suppresses human foam cell formation: Differential ability of AdipoRl and AdipoR2 to regulate inflammatory cytokine responses. Atherosclerosis 2012; 221: 66 - 75.